Jacques Dumas Sells 7,167 Shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Stock

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) insider Jacques Dumas sold 7,167 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total transaction of $44,507.07. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jacques Dumas also recently made the following trade(s):

  • On Tuesday, January 30th, Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock. The stock was sold at an average price of $6.22, for a total transaction of $54,425.00.
  • On Tuesday, October 31st, Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock. The stock was sold at an average price of $6.03, for a total transaction of $52,762.50.

Shares of Tetraphase Pharmaceuticals Inc (TTPH) traded down $0.14 on Friday, reaching $5.39. 540,279 shares of the company’s stock traded hands, compared to its average volume of 366,890. Tetraphase Pharmaceuticals Inc has a 52 week low of $3.65 and a 52 week high of $9.93. The firm has a market cap of $278.10, a PE ratio of -1.88 and a beta of 2.29.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The company had revenue of $4.10 million for the quarter, compared to analysts’ expectations of $1.59 million. During the same quarter in the previous year, the company posted ($0.58) EPS. The firm’s quarterly revenue was up 355.6% on a year-over-year basis. sell-side analysts expect that Tetraphase Pharmaceuticals Inc will post -2.88 EPS for the current fiscal year.

TTPH has been the subject of several recent analyst reports. HC Wainwright boosted their price target on shares of Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, November 6th. Zacks Investment Research lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 6th. BidaskClub lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. Finally, ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $15.15.

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Tetraphase Pharmaceuticals during the 3rd quarter worth $107,000. Brighton Jones LLC acquired a new stake in Tetraphase Pharmaceuticals during the 3rd quarter worth $108,000. AXA acquired a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth $132,000. Virtu KCG Holdings LLC acquired a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth $147,000. Finally, Voya Investment Management LLC boosted its position in shares of Tetraphase Pharmaceuticals by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares during the last quarter. 58.57% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/04/jacques-dumas-sells-7167-shares-of-tetraphase-pharmaceuticals-inc-ttph-stock.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply